Home » Stocks » Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. (PIRS)

Stock Price: $2.79 USD 0.09 (3.33%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $2.70 -0.09 (-3.23%) Aug 10, 5:05 PM

Stock Price Chart

Key Info

Market Cap 145.97M
Revenue (ttm) 51.00M
Net Income (ttm) -18.72M
Shares Out 52.32M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $2.79
Previous Close $2.70
Change ($) 0.09
Change (%) 3.33%
Day's Open 2.88
Day's Range 2.65 - 2.91
Day's Volume 471,735
52-Week Range 1.60 - 5.97

More Stats

Market Cap 145.97M
Enterprise Value 74.13M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.32M
Float 42.72M
EPS (basic) -0.42
EPS (diluted) -0.42
FCF / Share -1.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.26M
Short Ratio 5.83
Short % of Float 4.90%
Beta 1.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.86
PB Ratio 2.90
Revenue 51.00M
Operating Income -20.33M
Net Income -18.72M
Free Cash Flow -56.76M
Net Cash 71.84M
Net Cash / Share 1.37
Gross Margin 90.75%
Operating Margin -39.87%
Profit Margin -42.30%
FCF Margin -111.30%
ROA -9.97%
ROE -46.81%
ROIC -36.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(186.74% upside)
Low
5.00
Current: $2.79
High
10.00
Target: 8.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue46.2829.1025.285.832.935.3712.43
Revenue Growth59.03%15.14%333.46%98.88%-45.35%-56.83%-
Gross Profit46.2829.1025.285.832.935.3712.43
Operating Income-27.16-30.83-14.59-22.76-13.68-7.200.55
Net Income-25.47-26.75-17.65-22.80-14.06-9.850.07
Shares Outstanding50.6353.0843.9341.7134.3913.8711.83
Earnings Per Share-0.56-0.50-0.40-0.55-0.41-0.710.01
Operating Cash Flow-52.47-1.0749.75-14.39-12.71-5.07-3.08
Capital Expenditures-2.46-1.70-1.95-0.56-0.62-0.27-0.05
Free Cash Flow-54.93-2.7647.80-14.95-13.33-5.33-3.13
Cash & Equivalents10412872.6329.3629.3518.473.76
Total Debt15.48----1.274.75
Net Cash / Debt88.6712872.6329.3629.3517.20-0.99
Assets14114110435.0633.9521.867.28
Liabilities89.7510192.359.842.823.856.69
Book Value51.3539.9411.5225.2331.1318.010.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pieris Pharmaceuticals, Inc.
Country United States
Employees 114
CEO Stephen S. Yoder

Stock Information

Ticker Symbol PIRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PIRS

Description

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.